The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

Aprea Therapeutics Reports Positive Phase 1 Trial Data for Cancer Drug APR-1051

Key Facts

1Aprea Therapeutics (APRE) confirmed a partial response (PR) in its Phase 1 ACESOT-1051 trial for the drug APR-1051.

2The drug APR-1051 targets WEE1 inhibition in biomarker-defined cancers, showing a favorable safety profile without class-limiting toxicity to date.

3The company expects to provide a further update on the clinical trial results in the second quarter of 2026.

Create Free Account

Version History

4 additional sources confirmed this story

Aprea Therapeutics (Nasdaq: APRE) announced positive early clinical data from its Phase 1 ACESOT-1051 trial evaluating the drug APR-1051. The study confirmed a partial response (PR) in patients with biomarker-defined cancers, suggesting potential efficacy for the WEE1 inhibitor. Notably, the drug demonstrated a favorable safety profile with no class-limiting toxicities reported to date. This clinical proof of concept is a significant milestone as the company seeks to establish the treatment as a best-in-class option with an improved therapeutic index. Aprea expects to provide a further update on the clinical trial results in the second quarter of 2026. Such positive early-stage data is typically viewed as a strong catalyst for clinical-stage biotech companies, bolstering investor confidence in the pipeline.